Evofem Biosciences Inc (NASDAQ:EVFM)
| 0.4119 Delayed Data As of Jan 27 |  -0.0117 / -2.76%Today’s Change | 0.36 Today|||52-Week Range 5.53 | +9.69% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $69.3M |
Company Description
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate) a hormone-free vaginal gel and EVO100 an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Contact Information
Evofem Biosciences, Inc. 12400 High Bluff Drive San Diego California 92130 |
Employees
Shareholders
| Individual stakeholders | 9.54% |
| Mutual fund holders | 8.96% |
| Other institutional | 13.52% |
Top Executives
| Saundra L. Pelletier | President, Chief Executive Officer & Director |
| Richard M. Murawski | Senior Vice President-Operations |
| Justin J. File | Chief Financial Officer |
| Brandi Howard | Head-Medical Affairs |
| Kelly Culwell | Chief Medical Officer |
